Skip to main content
. 2022 Jul 12:eabq3773. doi: 10.1126/science.abq3773

Fig. 5. COV44-62 and COV44-79 inhibit SARS-CoV-2 spike-mediated fusion and COV44-79 limits disease in a Syrian hamster model.

Fig. 5.

(A) Images of fusion between HeLa cells stably expressing SARS-CoV-2 spike (RFP) and HeLa cells stably expressing the ACE2 receptor (GFP) after counter-staining with Hoechst (blue). Cells were co-cultured in the presence of COV44-62, COV44-79 or without a mAb (control). Scale bar, 500 μm. (B) Fusion inhibition of six fusion peptide-specific mAbs in a quantitative assay. (C) Weight change for SARS-CoV-2 naïve animals versus virus-exposed animals that were mock-treated or treated with 16 mg/kg of mAb. Statistical significance for average body weight was analyzed across the 7-day time-course using a mixed-effects repeated measures model with Dunnett's post-test multiple comparison (n = 12 animals from Day 0-3 and n = 6 animals from Day 4-7). Error bars show mean ± SD. (D) Pathology scores for SARS-CoV-2 naïve animals versus virus-exposed animals that were mock-treated or treated with 16 mg/kg of mAb. Scores for interstitial pneumonia pathology (Days 3 and 7) based on gross pathology observations were statistically analyzed by a Kruskal-Wallis test with Dunn’s post-test multiple comparison (n = 6-12 animals per condition), between the mAb-treated and mock-treated groups on each day. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 and ns, not significant. Bars show median + interquartile range.